Farallon Capital Management’s Immunovant IMVT Stock Holding History

Farallon Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$38.4M	Buy	1,546,000 +1,534,000	+12,783%	+$39.7M	0.22%	48
2025 Q4	$305K	Hold	12,000	–	–	﹤0.01%	108
2025 Q3	$193K	Hold	12,000	–	–	﹤0.01%	125
2025 Q2	$192K	Hold	12,000	–	–	﹤0.01%	122
2025 Q1	$205K	Hold	12,000	–	–	﹤0.01%	120
2024 Q4	$297K	Hold	12,000	–	–	﹤0.01%	115
2024 Q3	$342K	Hold	12,000	–	–	﹤0.01%	117
2024 Q2	$317K	Buy	+12,000	New	+$341K	﹤0.01%	117
2024 Q1	–	Sell	-341,000	Closed	-$14.4M	–	183
2023 Q4	$14.4M	Sell	341,000 -163,000	-32%	-$6M	0.07%	74
2023 Q3	$19.3M	Buy	+504,000	New	+$11.4M	0.09%	76

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Farallon Capital Management's IMVT Position: Q1 2026 in Review

Farallon Capital Management increased its Immunovant (IMVT) stake by 12,783% in Q1 2026, buying an estimated $39.7M and bringing the position to 1,546,000 shares worth $38.4M. The position accounts for 0.22% of the portfolio, ranked #48.

Farallon Capital Management first reported a position in IMVT in Q3 2023 and has held it in 10 quarters since. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

Farallon Capital Management held 1,546,000 shares of Immunovant worth $38.4M as of Q1 2026.
Farallon Capital Management bought 1,534,000 Immunovant shares in Q1 2026, an estimated $39.7M.
Immunovant made up 0.22% of Farallon Capital Management's portfolio in Q1 2026, its #48 holding.
Farallon Capital Management first reported a position in Immunovant in Q3 2023 and has held it in 10 quarters since.
215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.